article Open AccessTop 10% cited

Thyrotoxicosis in patients with COVID-19: the THYRCOV study

European Journal of Endocrinology · 2020 · Vol. 183(4) · pp. 381–387

Andrea Lania✉(Humanitas University)Maria Teresa Sandri(Istituti di Ricovero e Cura a Carattere Scientifico)Miriam Cellini(Istituti di Ricovero e Cura a Carattere Scientifico)Marco Mirani(Istituti di Ricovero e Cura a Carattere Scientifico)Elisabetta Lavezzi(Humanitas University)Gherardo Mazziotti(Istituti di Ricovero e Cura a Carattere Scientifico)

View via DOI Full-text PDF

Abstract

This study provides first evidence that COVID-19 may be associated with high risk of thyrotoxicosis in relationship with systemic immune activation induced by the SARS-CoV-2 infection.

COVID-19 Clinical Research Studies Thyroid Disorders and Treatments Heme Oxygenase-1 and Carbon MonoxideCoronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MedicineInternal medicineEndocrinologyBetacoronavirusVirologyOutbreakDisease

MeSH terms

BetacoronavirusCOVID-19SARS-CoV-2AdultAge FactorsAgedAged, 80 and overFemaleHumansHypothyroidismMaleMiddle AgedPneumonia, ViralRetrospective StudiesRisk Factors

Citations

359

FWCI

7.44

field-weighted impact

References

Percentile

98%

vs. same field & year

Citations per year

References

Hypocortisolism in survivors of severe acute respiratory syndrome (SARS)